OligoMedic is a privately held Canadian company created in 2010 and focused on developing and commercializing medical devices.

OligoMedic's founders are biomaterials experts who have developed several devices for the orthopedic market.

OligoMedic's technology is based on injectable thermosensitive hydrogels (thermogels) that solidify at body-temperature.

OligoMedic's leading product JointRep™ is CE-marked, and patented and granted in all major countries.

JointRep™ is presently distributed to the orthopedic market to repair cartilage, with spectacular success in over 1900 patients.

JointRep™ can also be used to deliver platelet rich plasma (PRP) or adipose derived mesenchymal stem cells for various orthopedic applications such as tendon and meniscus treatment.

Controlled post-market clinical study for use of JointRep™ in conjunction with microfracture in grade III-IV knee cartilage lesions showed exceptional results in terms of pain reduction and mobility improvement for patients, and MRI evidence of hyaline cartilage regrowth.

JointRep™ - Cartilage Regeneration Technology

JointRep™ is an injectable implant. It is the first product to provide a minimally invasive curative treatment for traumatic or arthrosis cartilage defects of any size or grade. Established treatments at best alleviate pain and delay the progression of cartilage loss. Heavier alternatives include total joint replacement.

womacsubscores_12

JointRep™ is being tested in a controlled clinical study in Europe, to compare a JointRep™ + microfracture operation to an operation with standard microfracture alone, on 69 patients of ages 18-75 with grade III-IV cartilage lesions unrestricted in size.

The patients had to follow a moderate two week rehab protocol, in contrast to a stringent 8 week rehab protocol in conventional microfracture.

The results reported through WOMAC scores indicate near-elimination of symptoms at 6 and 12 months in the groups treated with JointRep™ (right columns in the diagram on the left).

These results are substantiated with MRI evidence of genuine hyaline cartilage regrowth.

  • JointRep™ is a thermosensitive bioadhesive hydrogel that rapidly solidifies when heated to body temperature. It is applied directly onto cartilage lesions and sticks firmly. It provides a scaffold matrix for chondrocyte proliferation following microfracture.
  • JointRep™ is administered in a one-step procedure as part of a standard arthroscopy, adding only a few minutes to the operation.
  • The operation is performed under local anesthesia and the patient is released the same day and allowed total load ambulation with contralateral crutch after 90 minutes.
  • JointRep™ can be applied to lesions of any size or shape in any joint.
jointrepinvers

JointRep™ rapidly forms a solid hydrogel when implanted in cartilage defect.

  • No technical hurdles: JointRep™ should be stored between 2 and 8°C, but can be transported at ambient temperature.
  • Can be used without planning. Preparation time is between 3 and 5 minutes, enabling the physician to use it ad-hoc if defects are noticed in the course of a routine arthroscopic inspection or treatment (a study of over 30,000 arthroscopies in the United States has revealed an average of 2.7 defects in 63% of patients).
  • Unlike a viscosupplement, JointRep™ directly repairs affected cartilage.
  • JointRep™ is currently not licenced for sale in the USA and Canada.

Second look arthroscopy: cartilage regrown with JointRep™ is practically indistinguishable after 12 months from healthy pre-existing cartilage.

From left to right:

Defect in intercondylar notch prepared for JointRep™.   Defect filled with material.  Defect one year after.
1.Healthy cartilage 2.Defect.

oligo_one_year

Video Gallery

Arthroscopic lavage/debridement operation with JointRep™

This procedure is used to treat less severe chondropathies like symptomatic grade I-II osteoarthritis. There is no cartilage regrowth but lasting pain relief after 2-3 months. The age limit is 55.

With Dr. Nicolas Duval, Orthopedist


Standard Arthroscopic operation (Lavage/debridement)


Preparation and injection of JointRep™ implant


Arthroscopic JointRep™ operation with microfracture

This procedure is used to treat more severe chondropathies like grade III-IV osteoarthritis. The rehab period is very short, the pain relief is very quick and there is genuine regrowth of hyaline cartilage. The age limit is 75.

With Dr. Gennaro Pipino, full professor of orthopedic surgery, University of Lugano (Switzerland)


View from the operation room


Operation screen


Total weight ambulation with contralateral cane


90 minutes after the operation.

Demo: mixing JointRep™ components


Patients

One month after knee osteoarthritis treatment with microfracture + JointRep™.


A happy patient's post to Facebook three weeks after his microfracture + JointRep™.


News and Updates

2016
Other clinical trials on different indications are planned and will be disclosed when protocols are defined. Planning formal clinical trials for intervertebral disc regeneration using JointRep™ mixed with autologous stem cells.

2016
Preliminary steps taken toward procedures with FDA for market approval in the US.

2016
Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, Central and South America including Brazil.

2015
European controlled clinical trial: 69 patients, and comparing microfracture to microfracture & JointRep™. First study results will be published during Winter-2016.

2014
Initial experimentation with JointRep™ and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
2013
Structured OligoMedic for strategic partnership and initiated clinical trials and post market evaluation.
2012
Manufacturing, packaging, and shipping (at ambient temperature!) processes defined. Obtained CE mark in October.

2011
Follow up pre-clinical study on Health Canada SAP.

2010
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep™ operation. 

We succeeded in premixing JointRep™ with platelet rich plasma (PRP) while maintaining all the product's properties. The same can be done with bone marrow extract. This opens the possibility of using JointRep™ to deliver PRP or adipose derived mesenchymal cells for various orthopedic applications such as tendon and meniscus treatment.

 


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of PRP (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.

 


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of bone marrow extract (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.

Management Team

Amine

Dr. Amine Selmani, PhD President/CEO

Chenite

Dr. Abdelatif Chenite, PhD CTO

me_bw

Sam Alexandre Selmani VP International Markets

Cyril

Dr. Cyril Chaput, PhD, MBA VP  RA/QA

Monique

Mrs. Monique Jarry VP Finance & Corporate Development

yvesd

Dr. Yves De Backer Europe (CE) representative

Contact us

Don’t hes­i­tate to con­tact us for any enquiries you might have.

500 Cartier Blvd. № 113, Laval

(+1) 450-680-3371

info@oligomedic.com

Your Name (required)

Your Email (required)

Subject

Your Message